Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Top Cited Papers
- 28 April 2016
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 374 (17), 1609-1620
- https://doi.org/10.1056/nejmoa1514616
Abstract
Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement. We evaluated the two procedures in a randomized trial involving intermediate-risk patients. We randomly assigned 2032 intermediate-risk patients with severe aortic stenosis, at 57 centers, to undergo either TAVR or surgical replacement. The primary end point was death from any cause or disabling stroke at 2 years. The primary hypothesis was that TAVR would not be inferior to surgical replacement. Before randomization, patients were entered into one of two cohorts on the basis of clinical and imaging findings; 76.3% of the patients were included in the transfemoral-access cohort and 23.7% in the transthoracic-access cohort. The rate of death from any cause or disabling stroke was similar in the TAVR group and the surgery group (P=0.001 for noninferiority). At 2 years, the Kaplan–Meier event rates were 19.3% in the TAVR group and 21.1% in the surgery group (hazard ratio in the TAVR group, 0.89; 95% confidence interval [CI], 0.73 to 1.09; P=0.25). In the transfemoral-access cohort, TAVR resulted in a lower rate of death or disabling stroke than surgery (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P=0.05), whereas in the transthoracic-access cohort, outcomes were similar in the two groups. TAVR resulted in larger aortic-valve areas than did surgery and also resulted in lower rates of acute kidney injury, severe bleeding, and new-onset atrial fibrillation; surgery resulted in fewer major vascular complications and less paravalvular aortic regurgitation. In intermediate-risk patients, TAVR was similar to surgical aortic-valve replacement with respect to the primary end point of death or disabling stroke. (Funded by Edwards Lifesciences; PARTNER 2 ClinicalTrials.gov number, NCT01314313.)Keywords
This publication has 39 references indexed in Scilit:
- Predictors of Permanent Pacemaker Implantation in Patients With Severe Aortic Stenosis Undergoing TAVRJournal of the American College of Cardiology, 2014
- 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart DiseaseJournal of the American College of Cardiology, 2014
- Transcatheter Aortic-Valve Replacement with a Self-Expanding ProsthesisThe New England Journal of Medicine, 2014
- Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for SurgeryJournal of the American College of Cardiology, 2014
- The German Aortic Valve Registry (GARY): in-hospital outcomeEuropean Heart Journal, 2013
- Vascular Complications After Transcatheter Aortic Valve ReplacementJournal of the American College of Cardiology, 2012
- Guidelines on the management of valvular heart disease (version 2012)European Heart Journal, 2012
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsThe New England Journal of Medicine, 2011
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo SurgeryThe New England Journal of Medicine, 2010
- Silent and Apparent Cerebral Ischemia After Percutaneous Transfemoral Aortic Valve ImplantationCirculation, 2010